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PATHWAy oF THE MoNTH
Mammalian target of rapamycin (mToR) is a serine/threonine kinase 
that functions as a key regulatory protein in normal cell growth, 
survival, metabolism, development, and angiogenic pathways. 
Deregulation of these processes is a required hallmark of cancer, and 
dysregulation of mToR signaling frequently occurs in a wide vari-
ety of malignancies, including lung cancer. Targeting of mToR is 
thus an attractive strategy in the development of therapeutic agents 
against lung cancer. In this review, the mToR-signaling pathway is 
described, highlighting opportunities for therapeutic intervention and 
biomarker analysis, and clinical trials in lung cancer including both 
non–small cell lung cancer and small cell lung cancer.
Key Words: Mammalian target of rapamycin, Non-small cell lung 
cancer, Small cell lung cancer, Rapamycin, Sirolimus.
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Treatment with conventional chemotherapy for advanced non–small cell lung cancer (NSCLC) has reached a thera-
peutic plateau with a median survival time of 10 to 12 months. 
Thus, the need for new therapeutic opportunities is great, and 
the introduction of targeted therapies for subgroups of patients 
has already demonstrated great promise. one of the most 
promising targets identified in general is mammalian target of 
rapamycin (mToR), which is found to be activated in a sub-
stantial number of lung cancer cases as well. This review gives 
a background to the mToR pathway and describes the current 
clinical development of mToR inhibitors in the treatment of 
lung cancer, including biomarker analysis.
mTOR SIGNALING PATHWAY
“Target of rapamycin” is the protein target of rapamy-
cin, an antifungal metabolite originating from Easter Island 
(“Rapa Nui” in the native language), which was later found 
to have immunosuppressive and antiproliferative properties.1 
The mammalian homologue, mToR, is a 289 kDa protein with 
serine/threonine kinase activity. The mToR protein functions 
in two different complexes, mToRC1 and mToRC2. These 
mToR complexes play an integral role in the regulation of many 
cellular processes including protein synthesis, autophagy, lipid 
synthesis, mitochondrial metabolism/biogenesis, and cell cycle. 
Both mToR complexes are important for maintaining cellular 
homeostasis and the growth of many types of cancer, but with 
different mechanisms of action. mToRC1 is involved in regu-
lating cell size, whereas mToRC2 is involved in regulating cell 
shape through actin cytoskeleton reorganization.
Activation of mToR is initiated by ligand stimulation of 
one of several different membrane-bound growth factor recep-
tors, e.g., receptors for epidermal growth factor and insulin-like 
growth factor-1 and -2 (IGF-1 and -2). This receptor stimula-
tion leads to activation of phosphatidylinositol 3-kinase (PI3-K), 
which in turn will activate the downstream effector Akt (also 
known as protein kinase B), a master regulator of cell survival at 
multiple levels. Akt phosphorylates and suppresses the activity of 
the downstream tuberous sclerosis complex 1 (hamartin) and 2 
(tuberin)(TSC1/2), thereby leading to Rheb-mediated activation 
of mToR.2 This TSC1/2 complex functions as a key player in 
the regulation of the mToR pathway by mediating inputs from 
the PI3-K/phosphatase and tensin homologue (PTEN)/Akt and 
Ras/Erk1/2 signaling pathways. In cellular stress conditions the 
TSC1/2 complex is activated by the tumor suppressor serine/
threonine kinase 11 (liver kinase B1 [LKB1])–adenosine mono-
phosphate-activated protein kinase (AMPK) pathway, leading to 
the suppression of the activity of Rheb and switching off mToR-
mediated signals.3 The two major substrates of mToRC1 are 
S6K1 and 4E-BP1, which upon phosphorylation initiate eIF4E-
mediated cap-dependent transcription and translation of a wide 
variety of proteins. Genes that are sensitive to eIF4E-mediated 
translation cover a range of cellular functions, including cell-
cycle control (cyclin D1), angiogenesis (vascular endothelial 
growth factor), and apoptosis (survivin and Mcl-1). mToRC2 
has other substrates than mToRC1, and is known to phosphory-
late and activate Akt and Protein Kinase C (PKC) 4 (Fig. 1).
DEREGULATION OF mTOR PATHWAY IN 
LUNG CANCER
Abberant activation of the Akt/mToR pathway is com-
monly observed in lung cancer.1 Deregulated PI3-K/Akt/
mToR activity is known to contribute to lung cancer develop-
ment and maintenance, and the most downstream effector, eIF-
4E, is (1) capable of transforming cells, (2) overexpressed in 
both squamous lung carcinoma and adenocarcinoma, and (3) a 
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poor prognostic factor.1,5,6 Several lines of evidence support a 
role for the mToR pathway in lung carcinogenesis by means of 
its coupling with eIF-4E, which in numerous studies has been 
shown to function as an oncogene.7 eIF-4E expression in bron-
chial adenocarcinomas (but not squamous cell carcinomas) was 
found to be substantially higher than in the normal lung,8 and 
in an another study of adenocarcinomas eIF-4E expression was 
found to be elevated and specifically associated with histologi-
cal grade and invasiveness of the tumor.9 Several negative regu-
lators of mToR signaling, including PTEN and LKB1, act as 
tumor suppressors and have been found to be frequently mutated 
in lung cancer, indicating a role of the mToR pathway in lung 
carcinogenesis.2,3 Furthermore, in a transgenic mice model 
overexpression of IGF-1, a major activator of the Akt/mToR 
pathway, significantly increased the incidence of premalignant 
adenomatous hyperplastic lesions.10 Further evidence for a role 
of the mToR pathway in lung tumorigenesis comes from studies 
of the activation status of Akt, the upstream regulator of mToR, 
in bronchial epithelial lesions, showing an increased activity 
compared with normal and hyperplastic bronchial epithelia. 
Also, there was a similar frequency of activated Akt in low-
stage tumors (stage I/II) and high-stage tumors (stage III/IV), 
indicating that activated Akt/mToR pathway is an early event 
in tumor progression. Activation of Akt correlated well with 
phosphorylation of downstream mToR.11 Another study used 
the K-rasLA1 mice model in which somatic activation of the 
FIGURE 1. mTOR-signaling network. Activated growth factor receptors trigger activation of the PI3K/Akt pathways and the Ras/
MEK/Erk pathway. Activated Akt leads to increased mTOR activity through signaling by means of the TSC1/2 complex. mTOR 
then phosphorylates S6K1 and 4E-BP1, resulting in increased gene transcription, cell growth, and cell proliferation. PI3-K, phos-
phatidylinositol 3-kinase; AMPK, adenosine mono-phosphate-activated protein kinase; LKB1, liver kinase B1; PTEN, phosphatase 
and tensin homologue; STRAD, Ste20-like adaptor protein; TSC, tuberous sclerosis complex; EGFR, epidermal growth factor 
receptor; mTOR, mammalian target of rapamycin; m, signaling proteins frequently mutated in lung cancer; bm, potential as bio-
marker; Ras, ras2 Kirsten rat sarcoma viral oncogene homolog; MEK, MAPK/ERK kinase; Erk, extracellular signal-regulated kinase.
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v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-ras) 
oncogene induces morphologic changes in alveolar epithelial 
cells that recapitulate those of precursors of human lung adeno-
carcinoma. It was observed that the levels of phospho-S6, a 
downstream mediator of mToR, increased with malignant pro-
gression (normal alveolar epithelial cells to adenocarcinoma) 
with high levels of phospho-S6 in atypical alveolar hyperplasia, 
an early neoplastic change. Treatment with the rapamycin ana-
logue CCI-779, causing mToR inhibition, reduced the size and 
number of early epithelial neoplastic lesions.12 Furthermore, 
activation of the mToR pathway has been implicated in 
tobacco-related lung carcinogenesis. It was demonstrated that 
nicotine stimulated the Akt/mToR pathway in normal human 
bronchial epithelial cells, leading to induced survivin expres-
sion and increased survival potential of the cells. Small inter-
fering RNA-mediated down-regulation of survivin expression 
suppressed the tumorigenic potential of premalignant and 
malignant bronchial epithelial cells exposed to the tobacco 
components.13 In another study on factors influencing human 
bronchial epithelial cell growth it was found that fibronectin 
stimulates growth through activation of NF-B, which, in turn, 
is activated through PI3-K/Akt and integrin-dependent signals. 
Blocking both NF-B and PI3-K signals abolished the stimula-
tory effect of fibronectin on cell growth, suggesting that these 
signaling pathways are involved in the effect.14
Data suggest that mToR activation is associated with 
both KRAS and epidermal growth factor receptor (EGFR) 
mutation and may be a mechanism of resistance to treatment 
with EGFR inhibitors.15 There are also data demonstrating that 
mToR activation correlates with lymph node metastasis. In a 
report by Dobashi et al.,1 mToR was activated in as much as 
90% of adenocarcinomas, 40% of squamous cell carcinomas, 
and 60% of large cell carcinomas. In small cell lung cancer 
(SCLC), expression data are more scarce, but in a recent report, 
the Akt/mToR pathway was found to be widely expressed and 
activated in tumor specimens from SCLC patients. However, 
it did not correlate to survival.16 There are several studies on 
SCLC cell lines demonstrating that the PI3K/Akt/mToR path-
way is activated, including different mechanisms of activation, 
such as PTEN mutation and PI3-K overexpression.17
The activation of Akt through PI3-K is subject to neg-
ative regulation by the product of the PTEN gene on chro-
mosome 10,3 a tumor suppressor which acts by removing a 
phosphate group from PI3-K lipid product phosphatidylinosi-
tol 3,4,5-trisphosphate. Loss of PTEN in NSCLC is a frequent 
finding and has been associated with a worse prognosis and 
resistance to EGFR tyrosine kinase inhibitors (TKI).4 Another 
negative regulator of mToR is LKB1, also known as serine/
threonine kinase 11. LKB1 activates AMP-activated protein 
kinase through direct phosphorylation,which in turn phospho-
rylates TSC2, the guanosine triphosphate (GTP)-activating 
protein of Rheb, resulting in Rheb inactivation and mToR 
inhibition. LKB1 loss-of-function somatic mutations are fre-
quently observed in NSCLCs (20%–30%), and recent studies 
have identified LKB1 as an important factor in lung cancer, 
especially in the metastatic process.5
Epithelial-mesenchymal transition (EMT) leads to increased 
motility and invasive behavior in tumors and has been identified 
as a mechanism of resistance to EGFR TKIs.18 Transforming 
growth factor- has emerged as a major inducer of EMT through 
activation of downstream-signaling pathways, including Smad 
and non–Smad signaling pathways. Among the non–Smad path-
ways, the PI3K-Akt-mToR axis plays a major role in transform-
ing growth factor-–induced EMT.19 The exact role of mToR in 
EMT transition in lung cancer has not yet been studied in detail 
but is expected to be similar as in other cancer types.
There are indications that the mToR signaling pathway 
plays a central role in some characteristic clinical features of lung 
cancer. Lung cancer exhibits a particularly aggressive metastatic 
phenotype, and it was demonstrated that exposure of NSCLC cells 
to hypoxia or epidermal growth factor resulted in a significant up-
regulation of CXCR4 expression and chemotactic behavior by 
means of activation of hypoxia inducible factor-1 (HIF-1). The 
PI3-K inhibitors wortmannin and Ly294002 and the mToR inhib-
itor rapamycin inhibited activation of HIF-1 and consequently 
up-regulation of CXCR4 expression.20 Bone metastasis is a 
common phenomenon in lung cancer, contributing to significant 
morbidity and worse prognosis. Investigating cell signals that 
may contribute to increased osteoclast differentiation and conse-
quently bone resorption, phospholipase D (PLD)-induced Akt/
mToR activation was identified as one of the key signals. PLD 
inhibition completely decreased Akt and mToR phosphoryla-
tion, whereas a PI3-K inhibitor only partially decreased mToR 
phosphorylation, suggesting that mToR activation by PLD is 
through both PI3-K/Akt-dependent and -independent manner.21 
In another study, NSCLC tumors and cell lines were investigated 
for EphA2 mutations and a particular mutation, G391R, was 
found to activate the mToR pathway, leading to increased cell 
survival and an invasive phenotype.22
TARGETING THE mTOR PATHWAY
Sirolimus
The apparent importance of the mToR signaling  network 
in lung cancer makes its signaling components attractive targets 
for therapy. The antiproliferative and antitumor effects of siroli-
mus (rapamycin), a naturally occurring antibiotic produced by 
the bacterium Streptomyces hygroscopicus, have been evalu-
ated in numerous in vitro and in vivo models. However, there is 
very limited clinical data on sirolimus for the treatment of lung 
cancer, but clinical trials are ongoing (Table 1). on the basis 
of the already established sirolimus, several derivatives have 
been developed and investigated in preclinical and clinical 
studies including CCI-779 (Cell Cycle Inhibitor-779, temsi-
rolimus, ToRISEL; Pfizer, New york, Ny),  RAD001 (everoli-
mus, Afinitor;  Novartis Pharma AG, Basel, Switzerland), 
and AP23573 (Ariad Pharmaceuticals, Cambridge, MA). For 
ongoing clinical trials with mToR inhibitors, see Table 1.
CCI-779 (Temsirolimus)
CCI-779 is a water-soluble ester of sirolimus that is 
approved for the treatment of advanced renal cell carcinoma. 
The N0323 trial was a two-stage single-arm phase-II trial that 
evaluated the response and toxicity rates of CCI-779 admin-
istered as a frontline single-agent treatment for stage IIIB 
(pleural effusion) or stage IV NSCLC. Fifty-five patients were 
accrued and the median progression-free survival (PFS) and 
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overall survival (oS) were 2.3 and 6.6 months, respectively. 
An interesting clinical benefit was observed with four patients 
(8%) having confirmed partial responses and 15 patients (30%) 
with stable disease. The most common grade 3/4 toxicity 
included dyspnea (12%), fatigue (10%), hyperglycemia (8%), 
hypoxia (8%), nausea (8%), and rash/desquamation (6%). 
Although the study did not meet the predefined success criteria, 
single-agent CCI-779 showed activity similar to other signal 
transduction inhibitors, and had good tolerability.23 In a random-
ized phase II trial by the Eastern Cooperative oncology Group 
(E1500), 87 patients with extensive SCLC having received 
four to six cycles of cisplatin or carboplatin plus etoposide or 
irinotecan and with either stable or responding disease, were 
randomized between two different dose levels of temsirolimus. 
The study concluded that temsirolimus, given at 25 or 250 mg 
weekly, did not increase the PFS in this patient population. There 
were 86 patients with reported toxicities, 36 (42%) of whom 
had grade 3 toxicities, the most common of which were throm-
bocytopenia, hypophosphatemia, and fatigue. An additional 12 
(14%) had grade 4 toxicities, the most common of which was 
neutropenia. No patients experienced lethal toxicities.24
RAD001 (Everolimus)
RAD001 (everolimus) is an oral sirolimus analogue that 
is currently approved for the treatment of advanced renal cell 
carcinoma. Recently, a phase-II study evaluated everolimus in 
previously treated patients with relapsed SCLC. A total of 40 
patients were treated, and one patient (3%) showed a partial 
response, eight (23%) had stable disease; the primary endpoint 
disease control rate at 6 weeks was 26%, whereas median 
survival was 6.7 months, and median time to progression 
TABLE 1. Clinical Trials With mTOR Inhibitors in Lung Cancera
Trial Stage Patients (n) Intervention Main Endpoint
Sirolimus
Sarkaria et al.,45 phase I NSCLC III 7 Radiation 60 Gy/weekly cisplatin/sirolimus Safety, tolerability
NCT00993499 phase I 
(ongoing)
NSCLC IIIB/IV 42 Afatinib (BIBW 2992) /sirolimus Maximum tolerated dose
NCT00923273 phase I/II 
(ongoing)
Refractory/relapsed NSCLC 82 Pemetrexed/sirolimus Maximum tolerated dose, safety
Temsirolimus (CCI-779)
Hidalgo et al.,46 phase I Advanced cancer including 
lung cancer
63 CCI-779 (temsirolimus) Maximum tolerated dose, safety
Buckner et al.,47 phase I Advanced cancer including 
lung cancer
24 CCI-779 (temsirolimus) Maximum tolerated dose
Molina et al.23 phase II NSCLC IIIB/IV 55 CCI-779 (temsirolimus) Response rate, toxicity
Pandya et al.,24 phase II Extensive disease SCLC 87 CCI-779 (temsirolimus) PFS, toxicity
Bryce et al.,48 phase I Advanced solid tumors 
including lung cancer
48 CCI-779 (temsirolimus)/EKB-569  
(EGFR inhibitor)
Maximum tolerated dose
NCT00921310 phase I/II 
(ongoing)
Refractory/relapsed NSCLC 43 Pemetrexed/temsirolimus Maximum tolerated dose,  
response rate
Everolimus (RAD001)
Tarhini et al.,25 phase II Relapsed SCLC 40 Everolimus (RAD001) Disease control rate at 6 weeks
Ramalingam et al.,49 phase I Advanced NSCLC 24 Docetaxel/everolimus Recommended phase 2 doses
Vansteenkiste et al.,50 phase I NSCLC IIIB/IV 24 Pemetrexed/everolimus Cycle 1 dose-limiting toxicity
Soria et al.,26 phase II NSCLC IIIB/IV 85 Everolimus overall response rate 
Milton et al.,51 phase I NSCLC IIIB/IV 10 RAD001 (everolimus) Maximum tolerated dose,  
safety
Price et al.,29 phase II NSCLC IIIB/IV 62 Gefitinib/everolimus (RAD001) Response rate
NCT00401778 phase I 
(ongoing)
NSCLC I-IIIA 60 RAD001 (everolimus) Clinical response as measured  
by PET scan
NCT01317615 phase II 
(ongoing)
NSCLC IV LC-NEC 85 RAD001(everolimus)/carboplatin/
paclitaxel
Efficacy, safety
NCT01167530 phase I 
(ongoing)
NSCLC unresectable stage 
III/IV
34 RAD001 (everolimus)/radiotherapy
NCT01427946 phase I/II 
(ongoing)
NSCLC III/IV KRAS 
mutant
45 Retaspimycin HCl (IPI-504)/everolimus Safety/efficacy
NCT01063478 phase I 
(ongoing)
NSCLC II/III/Mx 24 RAD001 (everolimus)/radiotherapy/ 
chemotherapy
Safety
NCT01079481 phase I 
(ongoing)
SCLC relapsed or refractory 15 Everolimus/paclitaxel Maximum tolerated dose
aFor ongoing clinical trials, please refer to www.clinicaltrials.gov. Accessed December 20, 2011.
NSCLC, non–small cell lung cancer; EGFR, epidermal growth factor receptor; SCLC, small cell lung cancer; PFS, progression-free survival; PET, positron emission tomography.
951Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume  7, Number 6, June 2012 mTOR in Lung Cancer
was 1.3 months. Baseline S6 kinase protein expression was 
significantly higher in patients with disease control versus 
patients with progression (p  0.0093). Some grade 3 toxici-
ties were reported, including bone-marrow depression (throm-
bocytopenia [n  2] and neutropenia [n  2]), infection 
(n  2), pneumonitis (n  1), fatigue (n  1), elevated levels 
of transaminases (n  1), diarrhea (n  2), and acute renal 
failure (n  1). In conclusion, everolimus was well tolerated 
but had limited single-agent antitumor activity in unselected 
previously treated patients with relapsed SCLC.25 Another 
phase-II study of RAD001 assessed the efficacy of RAD001 
monotherapy, where advanced NSCLC patients with two 
or fewer prior chemotherapy regimens, one platinum based 
(stratum 1) or both chemotherapy and epidermal growth fac-
tor receptor TKIs (stratum 2), received RAD001 10 mg/day 
until progression or unacceptable toxicity. Primary objective 
was overall response rate. Eighty-five patients were included, 
and overall response rate was 4.7%, overall disease control 
rate 47.1%, and median PFSs 2.6 (stratum 1) and 2.7 months 
(stratum 2). Common events that were graded 3 or more were 
fatigue, dyspnea, stomatitis, anemia, and thrombocytopenia. 
Pneumonitis, probably or possibly related, mainly grade 1/2, 
occurred in 25% of patients. The study concluded that RAD001 
10 mg/day was well tolerated, showing modest clinical activ-
ity in pretreated NSCLC.26 Pneumonitis is a known side effect 
of inhibitors of mToR and has been described for sirolimus, 
temsirolimus, and everolimus. A recent retrospective study of 
patients with advanced NSCLC suggests that a mostly low-
grade pneumonitis with a possible or probable relationship to 
everolimus was relatively frequent, occurring in 25% of the 
evaluated patients, suggesting a need for monitoring of pul-
monary adverse events in future studies with everolimus.27
Combination Treatment With mTOR and 
EGFR Inhibitors
Increasing knowledge about mechanisms of resistance 
to EGFR-TKIs supports a significant role for the Akt/mToR 
pathway in resistance development,28 and has led to the initia-
tion of clinical trials evaluating the combination of EGFR-TKIs 
and mToR inhibitors. A phase-II trial assessed the efficacy 
of the combination of gefitinib and everolimus in patients 
with advanced NSCLC. Sixty-two patients were enrolled, and 
partial responses were seen in eight of 62 patients (response 
rate, 13%). Three partial responders had an EGFR mutation. 
Interestingly, both patients with a KRAS (G12F) mutation 
responded. The median time to progression was 4 months and 
the median overall survival was 12 months for all patients. 
By subgroups, the median overall survival was 27 months 
for patients with no prior chemotherapy and 11 months for 
patients previously treated with chemotherapy. Although the 
trial did not meet the pre-specified response  threshold to pur-
sue further study of the combination of gefitinib and everoli-
mus, further investigation of mToR inhibitors in patients with 
NSCLC with KRAS G12F-mutated tumors is warranted.29
Combination Treatment With mTOR and IGF-
1R Inhibitors
Thus far, limited anticancer therapeutic success with 
IGF-1R targeted therapy has been reported; also, there is 
limited knowledge about resistance mechanisms to IGF-1R 
directed therapy.30–33 one study on cixutumumab (IMC-A12), 
an anti-IGF-1R monoclonal antibody (mAb), demonstrated 
induced activation of Akt and mToR, resulting in de novo 
synthesis of EGFR, Akt1, and survivin proteins and activation 
of the EGFR pathway in cixutumumab-resistant head-neck 
carcinoma and NSCLC cells.34 Targeting mToR and EGFR 
pathways by treatment with rapamycin and cetuximab (an anti-
EGFR mAb), respectively, prevented cixutumumab-induced 
expression of EGFR, Akt, and survivin and induced synergis-
tic antitumor effects in vitro and in vivo. An ongoing phase-II 
study (NCT01016015) is evaluating the combination of temsi-
rolimus and cixutumumab in treatment of patients with locally 
advanced, metastatic, or recurrent soft-tissue sarcoma or bone 
sarcoma. Also, for mToR inhibitors a connection between 
mToR and IGF-1R signaling has been found. In rhabdomyo-
sarcoma cell lines and xenografts, rapamycin mediated Akt 
activation through an IGF-1R–dependent mechanism, report-
edly involving abrogation of a mToR-mediated negative feed-
back signal through S6K and Grb10.35,36 Combined mToR 
and IGF-1R inhibition with rapamycin and the anti-IGF-1R 
mAb h7C10, respectively, resulted in additive inhibition of 
cell growth and survival.37 Thus, combining an mToR inhibi-
tor and an IGF-1R antibody/inhibitor may be an appropriate 
strategy to enhance mToR-targeted anticancer therapy.
Other mTOR Inhibitors
Ridaforolimus (AP23573) is a novel non-prodrug siroli-
mus analogue that selectively targets mToR and has shown 
potent antitumor activity both in cell lines and in xenograft tumor 
models. It is currently under clinical evaluation, and in phase-I 
studies has shown good tolerability with dose-limiting stoma-
titis, in both single and combination treatments. Ridaforolimus 
has demonstrated clinical benefit in advanced soft-tissue sar-
coma and in hematological malignancies, and several phase-I 
studies in various tumor types are ongoing.38 Clinical data for 
treatment in lung cancer are yet to be reported.
mToRC1 is sensitive whereas mToRC2 is resistant to 
rapamycin and other rapalogs. Second-generation inhibitors of 
mToR, referred as mToR kinase domain inhibitors, are being 
developed that target rapamycin-resistant pathways by inhibit-
ing the adenosine-5’-triphosphate binding site of both mToRC1 
and mToRC2. Two such novel mToR inhibitors, CC-115, and 
CC-223 (Celgene), are currently under clinical investigation 
in phase-I trials in patients with advanced solid tumors, non-
Hodgkin’s lymphoma or multiple myeloma to assess safety and 
tolerability (NCT01353625 and NCT01177397, respectively). 
CC-115, being a dual DNA-protein kinase and mToR inhibi-
tor, differs from other mToR inhibitors whereas CC-223 is a 
dual mToR inhibitor targeting both mToRC1 and mToRC2. 
They both exist as oral formulations.
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Other Inhibitors of the mTOR Pathway
Alternative ways of inhibiting the mToR pathway 
include PI3-K inhibition. The first-generation PI3-K inhibi-
tors, Wortmannin and Ly2994002, proved unsuitable for clini-
cal use despite demonstrating preclinical antitumor activity.39 
Novel PI3-K inhibitors, including BKM120 (an oral pan-class 
I PI3-K inhibitor), XL 147 (an adenosine-5’-triphosphate-
competitive reversible PI3-K inhibitor), and GDC-0941 (a dual 
PI3K/mToR inhibitor) have been developed and early clinical 
trials in lung cancer and other solid tumors are ongoing, but 
data regarding lung cancer are still pending. Akt inhibition is 
another strategy to block signaling in the mToR pathway and is 
being explored in early clinical studies in lung cancer, includ-
ing MK2206 in advanced NSCLC patients who previously pro-
gressed on erlotinib treatment (www.clinicaltrials.gov).
BIOMARKERS
Promising yet limited success has been achieved in clin-
ical applications of mToR inhibitors. An important strategy 
in the evaluation of mToR inhibitors is the identification of 
patients who are most likely to benefit by using a biomarker 
approach. Several biomarkers have been developed to moni-
tor the effects of mToR inhibitors, including measurements 
by Western blotting or immunohistochemistry of S6K and 
4E-BP1 phosphorylation (see Fig. 1 for potential biomarkers). 
In one study, activation of S6K and/or 4E-BP1 was a deter-
minant of cisplatin resistance in NSCLC.40 Biomarker data 
are limited in lung cancer but some experience can be derived 
from studies of other tumor types. on investigating sensitiv-
ity to ridaforolimus in sarcoma and endometrial cancer cells, 
it was found that the proportion of cells in the G(0)–G(1) 
phase of the cell cycle before treatment correlated signifi-
cantly with ridaforolimus sensitivity, also including a higher 
expression of several G(1) phase cell-cycle proteins such as 
p21 and p27.41 Another study using a mammary carcinoma 
oncoMouse model demonstrated that the antitumor efficacy 
of temsirolimus was associated with significantly suppressed 
tumor vascular density and macrophage burden, two microen-
vironmental factors of importance for tumor progression.42 
An association with decreased levels of phospho-S6 proteins 
was also seen. There is a need for efficient biomarkers not 
only to predict who will benefit from chemotherapy but also 
to avoid the development of unnecessary toxicity. In one study 
in advanced NSCLC patients using single nucleotide poly-
morphism analysis, genetic variations within the PI3K/PTEN/
AKT/mToR signaling pathway associated with increased risk 
of toxicity from platinum-based chemotherapy.43 However, 
existing biomarkers have been found to be only partially pre-
dictive and additional biomarkers are warranted. For example, 
S6K activity showed reduction both in “sensitive” and “insen-
sitive” cells in a study on everolimus.34 S6K may also be a 
prognostic marker for clinical outcome independent of type 
of treatment, according to findings in both breast cancer and 
renal cancer patients.
Besides the classical mToR/S6K/4E-BP1 pathway, 
alternative biomarkers for response to mToR inhibitors 
have been explored in different tumor types. In a study 
on patients with persistent/recurrent epithelial ovarian 
cancer/primary peritoneal cancer, an association between 
positive pretreatment circulating tumor cells and lack 
of response to temsirolimus was indicated.44 Because of 
the inherent complexity in the regulation and function of 
mToR, a combined use of different classes of biomarkers 
may be needed to accurately predict responses to mToR 
inhibitors. Moreover, the molecular mechanisms involved 
in mToR activation, e.g., abrogation of PTEN function, 
may be tumor-specific. The mToR inhibitors will most 
likely show activity in selected patient populations with 
specific molecular alterations. Therefore, the importance 
of simultaneous development of predictive biomarkers is 
crucial in future clinical trials.
In conclusion, the mToR pathway plays a critical role in 
mediating proliferative and survival signals in cancer cells and 
has been shown to be an important factor in lung carcinogen-
esis and tumor progression,7 and in resistance to chemother-
apy and EGFR inhibitors.15 Several mToR-targeted agents are 
under clinical development, both in NSCLC and SCLC, given 
as single treatment or in combination with chemotherapeutic 
agents or EGFR-TKIs. So far, promising clinical data have 
been observed, including partial responses and manageable 
toxicity, stimulating further clinical development. To further 
enhance the clinical benefit of mToR inhibitors, there is a 
need to incorporate biomarker analyses in future clinical tri-
als, improving our ability to identify the optimal patients and 
dosing and combination strategies with other molecular-tar-
geted therapies.
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